Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Breast Neoplasms 2Recurrence 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Cancer Recurrent 1Neoplasm Metastasis 1Melanoma 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms, Male 1Breast Carcinoma In Situ 1

Interventions

poly(I).poly(c12,U) 1pembrolizumab 1mirabegron 1liposomal doxorubicin 1disitamab vedotin 1apatinib 1anlotinib 1Tocotrienols 1Platinum Compounds 1Paclitaxel 1Lenalidomide 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Cancer Recurrent × poly(I).poly(c12,U) × Clear all
NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

University of Pittsburgh

Phase 1/2 Active not recruiting
24 enrolled 59 charts
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡